Eximias Pharmaceutical Corporation
Berwyn
About Eximias Pharmaceutical Corporation
Eximias Pharmaceutical Corporation is a healthcare and pharmaceutical company. It focuses on the acquisition, development, and commercialization of unique oncology and infectious disease products. The company has three novel, late-stage products, THYMITAQ(R) and ORATAQ(TM) for oncology, and MACROTAC(TM) for oncology and infectious disease. THYMITAQ(R), the company's flagship product, is being evaluated in a Phase III ETHECC(C) trial for the treatment of patients with unresectable liver cancer. Eximias Pharmaceutical Corporation was founded in 1997. The company was founded by YM BioSciences on April 1, 2006.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Funding stage: M&A
- Last round: Seed (Apr 2004)
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/eximias-pharmaceutical-corporation-3324184 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.